Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Post-transcriptional modification of m6A methylase METTL3 regulates ERK-induced androgen-deprived treatment resistance prostate cancer
Yang Li, Shimiao Zhu, Yutong Chen, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 4
Open Access | Times Cited: 18

Showing 18 citing articles:

A Stapled Peptide Inhibitor Targeting the Binding Interface of N6‐Adenosine‐Methyltransferase Subunits METTL3 and METTL14 for Cancer Therapy
Zenghui Li, Yuqing Feng, Hong Han, et al.
Angewandte Chemie International Edition (2024) Vol. 63, Iss. 24
Closed Access | Times Cited: 16
Writers, readers, and erasers RNA modifications and drug resistance in cancer
Di Chen, Xinyu Gu, Yeltai Nurzat, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 14
Insulin‐Like Growth Factor 2 mRNA‐Binding Protein 2 (IGF2BP2) Promotes Castration‐Resistant Prostate Cancer Progression by Regulating AR‐V7 mRNA Stability
Taruna Saini, Devesh Srivastava, Rajnikant Raut, et al.
Cancer Reports (2025) Vol. 8, Iss. 2
Open Access | Times Cited: 1
FMNL2/SRC-mediated androgen receptor translocation into the nucleus promotes enzalutamide resistance of prostate cancer.
Jianpeng Yu, Yukui Gao, Mingpeng Zhang, et al.
iScience (2025), pp. 112205-112205
Open Access
Emerging importance of m6A modification in liver cancer and its potential therapeutic role
Tao Chen, Wufei Ye, Songsen Gao, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025), pp. 189299-189299
Closed Access
Icariin-Curcumol promotes docetaxel sensitivity in prostate cancer through modulation of the PI3K-Akt signaling pathway and the Warburg effect
Wenjing Xu, Jin Ding, Shida Kuang, et al.
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 12
A Stapled Peptide Inhibitor Targeting the Binding Interface of N6‐Adenosine‐Methyltransferase Subunits METTL3 and METTL14 for Cancer Therapy
Zenghui Li, Yuqing Feng, Hong Han, et al.
Angewandte Chemie (2024) Vol. 136, Iss. 24
Closed Access | Times Cited: 4
Histone lactylation regulates early embryonic development through m6A methyltransferase METTL3 in goats
Dongxu Li, Zifei Liu, Minghui Zhu, et al.
International Journal of Biological Macromolecules (2025), pp. 142858-142858
Closed Access
METTL3-mediated m6A modification of circGLIS3 promotes prostate cancer progression and represents a potential target for ARSI therapy
Xiaofeng Cheng, Heng Yang, Yujun Chen, et al.
Cellular & Molecular Biology Letters (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 3
METTL3 inhibitor suppresses the progression of prostate cancer via IGFBP3/AKT pathway and synergizes with PARP inhibitor
Xin Chen, Miaomiao Wang, Haoran Wang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 179, pp. 117366-117366
Open Access | Times Cited: 3
Peptide degrader‐based targeting of METTL3/14 improves immunotherapy response in cutaneous melanoma
Hong Han, Zenghui Li, Yuqing Feng, et al.
Angewandte Chemie International Edition (2024) Vol. 63, Iss. 48
Closed Access | Times Cited: 2
Influence of RNA Methylation on Cancerous Cells: A Prospective Approach for Alteration of In Vivo Cellular Composition
Manali Rupareliya, Pravin Shende
Advances in experimental medicine and biology (2024)
Closed Access | Times Cited: 2
Cell division cycle 42 effector protein 4 inhibits prostate cancer progression by suppressing ERK signaling pathway
Xiaowen Zhang, Tao Yu, Guojun Gao, et al.
Biomolecules and Biomedicine (2023) Vol. 24, Iss. 4, pp. 840-847
Open Access | Times Cited: 2
The m6A regulators in prostate cancer: molecular basis and clinical perspective
Yu Cao, Man Jia, Chunyan Duan, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Androgens have therapeutic potential in T2 asthma by mediating METTL3 in bronchial epithelial cells
Zhifeng Chen, Yulin Shang, Wentao Duan, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113322-113322
Closed Access
Peptide degrader‐based targeting of METTL3/14 improves immunotherapy response in cutaneous melanoma
Hong Han, Zenghui Li, Yuqing Feng, et al.
Angewandte Chemie (2024) Vol. 136, Iss. 48
Open Access
The current landscape of m6A modification in urological cancers
Yaohui Zeng, Cai Lv, Bangbei Wan, et al.
PeerJ (2023) Vol. 11, pp. e16023-e16023
Open Access | Times Cited: 1
A Stapled Peptide Inhibitor of METTL3-METTL14 for Cancer Therapy
Zenghui Li, Yuqing Feng, Hong Han, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Page 1

Scroll to top